Passa al contenuto
Merck
Tutte le immagini(3)

Key Documents

WH0008658M1

Sigma-Aldrich

Monoclonal Anti-TNKS antibody produced in mouse

clone 1A2, purified immunoglobulin, buffered aqueous solution

Sinonimo/i:

Anti-PARP5A, Anti-PARP5a, Anti-PARPL, Anti-TIN1, Anti-TINF1, Anti-TNKS1, Anti-tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Numero MDL:
MFCD02686643
Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

mouse

Livello qualitativo

100

Coniugato

unconjugated

Forma dell’anticorpo

purified immunoglobulin

Tipo di anticorpo

primary antibodies

Clone

1A2, monoclonal

Forma fisica

buffered aqueous solution

Reattività contro le specie

human

tecniche

immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
indirect ELISA: suitable
western blot: 1-5 μg/mL

Isotipo

IgG2aκ

N° accesso Genebanck

NM_003747

N° accesso UniProt

O95271

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... TNKS(8658)

Descrizione generale

The gene TNKS (tankyrase) is mapped to human chromosome 8p23.1. It belongs to the PARP (poly (ADP-ribose) polymerase) family of proteins and is responsible for addition of poly (ADP-ribose) (PAR) to substrate proteins. The TNKS protein contains ankyrin repeats and a sterile α-motif (SAM).

Immunogeno

TNKS (NP_003738, 1017 a.a. ~ 1124 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Sequence
TERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEE

Azioni biochim/fisiol

TNKS (tankyrase) is a regulator of Wnt-signaling. It negatively regulates Axin1, thereby suppressing β-catenin degradation and causing hyperactivation of Wnt/β-catenin signaling. TNKS controls cell death and telomere length. It might also be associated with osteoarthritis. In murine lung cancer model, silencing of this gene reduces lung cancer cell growth. Application of TNKS inhibitor suppresses growth of hepatocellular carcinoma cells. Absence of TNKS activity helps in replication of human cytomegalovirus (HCMV).

Stato fisico

Solution in phosphate buffered saline, pH 7.4

Note legali

GenBank is a registered trademark of United States Department of Health and Human Services

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

10 - Combustible liquids

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Genetic variants in eleven telomere-associated genes and the risk of incident cardio/cerebrovascular disease: The Women's Genome Health Study.
Zee RY, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 412, 199-202 (2011)
Tankyrase 1 polymorphism associated with an increased risk in developing non-small cell lung cancer in a Chinese population: a proof-of-principle study.
Wang Y, et al.
International Journal of Clinical and Experimental Pathology, 8, 10500-10511 (2015)
A genome-wide association study of copy-number variation identifies putative loci associated with osteoarthritis in Koreans.
Moon S, et al.
BMC Musculoskelet. Disord., 16, 76-76 (2015)
Sharon McGonigle et al.
Oncotarget, 6(38), 41307-41323 (2015-10-30)
Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment. Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2
Tankyrase inhibitors attenuate WNT/?-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L, et al.
Oncotarget, 6, 25390-25401 (2015)

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.